J.C. Ruffinelli

789 total citations
27 papers, 271 citations indexed

About

J.C. Ruffinelli is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, J.C. Ruffinelli has authored 27 papers receiving a total of 271 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in J.C. Ruffinelli's work include Colorectal Cancer Treatments and Studies (9 papers), Lung Cancer Treatments and Mutations (6 papers) and Cancer Treatment and Pharmacology (5 papers). J.C. Ruffinelli is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Lung Cancer Treatments and Mutations (6 papers) and Cancer Treatment and Pharmacology (5 papers). J.C. Ruffinelli collaborates with scholars based in Spain, United States and Japan. J.C. Ruffinelli's co-authors include Rona Yaeger, Takeshi Kato, Julien Taı̈eb, Jean-Claude Vedovato, Janet Graham, Thierry André, Evaristo Maiello, Josep Tabernero, Takayuki Yoshino and Axel Grothey and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and British Journal of Cancer.

In The Last Decade

J.C. Ruffinelli

26 papers receiving 267 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J.C. Ruffinelli Spain 9 180 102 90 59 45 27 271
Yang Lv China 12 189 1.1× 80 0.8× 98 1.1× 29 0.5× 76 1.7× 24 312
Ei Yamaki Japan 8 143 0.8× 133 1.3× 129 1.4× 44 0.7× 45 1.0× 29 367
Takuro Mizukami Japan 12 213 1.2× 175 1.7× 152 1.7× 75 1.3× 73 1.6× 48 427
Valeria Smiroldo Italy 10 199 1.1× 85 0.8× 70 0.8× 41 0.7× 45 1.0× 28 280
Ramón Barceló Spain 9 158 0.9× 159 1.6× 34 0.4× 29 0.5× 21 0.5× 28 293
Rui Kitadai Japan 10 213 1.2× 161 1.6× 35 0.4× 19 0.3× 40 0.9× 27 296
Juan José Reina Spain 6 280 1.6× 90 0.9× 29 0.3× 51 0.9× 14 0.3× 8 324
Jean Philippe Metges France 8 224 1.2× 124 1.2× 110 1.2× 27 0.5× 76 1.7× 23 343
Shu-Kui Qin China 5 179 1.0× 129 1.3× 38 0.4× 25 0.4× 23 0.5× 11 270
Takefumi Yoshida Japan 11 212 1.2× 58 0.6× 98 1.1× 70 1.2× 97 2.2× 38 394

Countries citing papers authored by J.C. Ruffinelli

Since Specialization
Citations

This map shows the geographic impact of J.C. Ruffinelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.C. Ruffinelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.C. Ruffinelli more than expected).

Fields of papers citing papers by J.C. Ruffinelli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.C. Ruffinelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.C. Ruffinelli. The network helps show where J.C. Ruffinelli may publish in the future.

Co-authorship network of co-authors of J.C. Ruffinelli

This figure shows the co-authorship network connecting the top 25 collaborators of J.C. Ruffinelli. A scholar is included among the top collaborators of J.C. Ruffinelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.C. Ruffinelli. J.C. Ruffinelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kopetz, Scott, Rocio García‐Carbonero, Sae‐Won Han, et al.. (2025). Precemtabart tocentecan (M9140), an anti-CEACAM5 ADC with exatecan payload, in patients with metastatic colorectal cancer (mCRC): Results from the dose optimization of the phase 1 PROCEADE CRC-01 study.. Journal of Clinical Oncology. 43(16_suppl). 3038–3038. 1 indexed citations
2.
Li, Bob T., Jeffrey Clarke, Enriqueta Felip, et al.. (2024). Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial.. Journal of Clinical Oncology. 42(16_suppl). 8512–8512. 8 indexed citations
3.
Micke, Patrick, et al.. (2024). The histological growth patterns in liver metastases from colorectal cancer display differences in lymphoid, myeloid, and mesenchymal cells. SHILAP Revista de lepidopterología. 5(12). e70000–e70000. 1 indexed citations
4.
Yaeger, Rona, Corey J. Langer, J.C. Ruffinelli, et al.. (2024). A phase 1b study of sotorasib combined with panitumumab as second-line treatment of KRAS G12C-mutated colorectal cancer.. Journal of Clinical Oncology. 42(3_suppl). 128–128. 3 indexed citations
5.
Loong, Herbert H., Gennaro Daniele, Ticiana Leal, et al.. (2023). 1320MO Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088. Annals of Oncology. 34. S761–S762. 4 indexed citations
6.
Molina, Kevin, Susana Padrones, J.C. Ruffinelli, et al.. (2023). Stereotactic Body Radiotherapy versus Surgery for Lung Metastases from Colorectal Cancer: Single-Institution Results. Cancers. 15(4). 1195–1195. 5 indexed citations
7.
Clarke, Jeffrey, Enriqueta Felip, B.T. Li, et al.. (2023). MA06.05 CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC. Journal of Thoracic Oncology. 18(11). S118–S119. 12 indexed citations
8.
Cutsem, Eric Van, Julien Taı̈eb, Rona Yaeger, et al.. (2023). ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer. Journal of Clinical Oncology. 41(14). 2628–2637. 63 indexed citations
9.
Díaz‐Valdivia, Natalia, Carlos Borau, José Ramírez, et al.. (2022). 3D collagen migration patterns reveal a SMAD3-dependent and TGF-β1-independent mechanism of recruitment for tumour-associated fibroblasts in lung adenocarcinoma. British Journal of Cancer. 128(6). 967–981. 3 indexed citations
10.
Mezheyeuski, Artur, Patrick Micke, J.C. Ruffinelli, et al.. (2022). Spatial Immunology in Liver Metastases from Colorectal Carcinoma according to the Histologic Growth Pattern. Cancers. 14(3). 689–689. 3 indexed citations
11.
Bosch‐Barrera, Joaquim, Sara Verdura, J.C. Ruffinelli, et al.. (2021). Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer. Cancers. 13(16). 4168–4168. 11 indexed citations
12.
13.
Grande, Enrique, Rocio García‐Carbonero, Àlex Teulé, et al.. (2021). 575TiP Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914). Annals of Oncology. 32. S624–S625. 2 indexed citations
14.
Guerrero‐Pérez, Fernando, Inmaculada Peiró, Àlex Teulé, et al.. (2021). Ectopic Cushing’s syndrome due to thymic neuroendocrine tumours: a systematic review. Reviews in Endocrine and Metabolic Disorders. 22(4). 1041–1056. 10 indexed citations
15.
Ruffinelli, J.C., et al.. (2020). New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients. Expert Review of Gastroenterology & Hepatology. 15(1). 65–79. 2 indexed citations
16.
Grande, Enrique, Àlex Teulé, Teresa Alonso‐Gordoa, et al.. (2020). The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407). The Oncologist. 25(9). 745–e1265. 24 indexed citations
17.
Grothey, Axel, Josep Tabernero, Julien Taı̈eb, et al.. (2020). LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer. Annals of Oncology. 31. S242–S243. 33 indexed citations
18.
Rullan, Antonio, Maria Saigí, Inmaculada Peiró, et al.. (2019). Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. BMC Cancer. 19(1). 165–165. 26 indexed citations
19.
Vilariño, Noelia, Marta Simó, Roser Velasco, et al.. (2019). MA13.03 Retrospective Study of Intrathecal Therapy for Non-Small Cell Lung Cancer (NSCLC) Patients with Leptomeningeal Carcinomatosis. Journal of Thoracic Oncology. 14(10). S300–S301. 1 indexed citations
20.
Antonio, Maite, Jenniffer Linares, J.C. Ruffinelli, et al.. (2018). Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer. British Journal of Cancer. 118(5). 639–647. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yang Lv Breakdown of academic impact, for papers by Ei Yamaki Breakdown of academic impact, for papers by Takuro Mizukami Breakdown of academic impact, for papers by Valeria Smiroldo Breakdown of academic impact, for papers by Ramón Barceló Breakdown of academic impact, for papers by Rui Kitadai Breakdown of academic impact, for papers by Juan José Reina Breakdown of academic impact, for papers by Jean Philippe Metges Breakdown of academic impact, for papers by Shu-Kui Qin Breakdown of academic impact, for papers by Takefumi Yoshida
Rankless by CCL
2026